MESO Q1 2024 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+17.4% YoY

Gross Profit

-$8M-472.4% margin

Operating Income

-$20M-1184.6% margin

Net Income

-$16M-960.4% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-20.8%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$670M

Total Liabilities

$162M

Stockholders' Equity

$509M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+17.4%
Gross Profit	-$8M	-$9M	+12.7%
Operating Income	-$20M	-$16M	-25.4%
Net Income	-$16M	-$17M	+3.6%